Moschos SJ - Search Results

1

Pharmacodynamic (phase 0) study using etaracizumab in advanced melanoma.

Moschos SJ, Sander CA, Wang W, Reppert SL, Drogowski LM, Jukic DM, Rao UN, Athanassiou C, Buzoianu M, Mandic M, Richman L, McKinney L, Leininger J, Tice DA, Hammershaimb L, Kirkwood JM. Moschos SJ, et al. J Immunother. 2010 Apr;33(3):316-25. doi: 10.1097/CJI.0b013e3181c1f216. J Immunother. 2010. PMID: 20445352 Clinical Trial.

2

Present status and future prospects for adjuvant therapy of melanoma: time to build upon the foundation of high-dose interferon alfa-2b.

Moschos SJ, Kirkwood JM, Konstantinopoulos PA. Moschos SJ, et al. J Clin Oncol. 2004 Jan 1;22(1):11-4. doi: 10.1200/JCO.2004.10.952. Epub 2003 Dec 9. J Clin Oncol. 2004. PMID: 14665613 No abstract available.

3

Melanoma.

Moschos SJ, Konstantinopoulos PA, Kirkwood JM. Moschos SJ, et al. Cancer Chemother Biol Response Modif. 2005;22:563-90. Cancer Chemother Biol Response Modif. 2005. PMID: 16110629 Review. No abstract available.

4

Interferons in the treatment of solid tumors.

Moschos S, Varanasi S, Kirkwood JM. Moschos S, et al. Cancer Treat Res. 2005;126:207-41. doi: 10.1007/0-387-24361-5_9. Cancer Treat Res. 2005. PMID: 16209068 Review. No abstract available.

5

Strategies for the development of more effective adjuvant therapy of melanoma: current and future explorations of antibodies, cytokines, vaccines, and combinations.

Kirkwood JM, Moschos S, Wang W. Kirkwood JM, et al. Clin Cancer Res. 2006 Apr 1;12(7 Pt 2):2331s-2336s. doi: 10.1158/1078-0432.CCR-05-2538. Clin Cancer Res. 2006. PMID: 16609054 Review.

6

Neoadjuvant treatment of regional stage IIIB melanoma with high-dose interferon alfa-2b induces objective tumor regression in association with modulation of tumor infiltrating host cellular immune responses.

Moschos SJ, Edington HD, Land SR, Rao UN, Jukic D, Shipe-Spotloe J, Kirkwood JM. Moschos SJ, et al. J Clin Oncol. 2006 Jul 1;24(19):3164-71. doi: 10.1200/JCO.2005.05.2498. J Clin Oncol. 2006. PMID: 16809739 Clinical Trial.

7

SAGE and antibody array analysis of melanoma-infiltrated lymph nodes: identification of Ubc9 as an important molecule in advanced-stage melanomas.

Moschos SJ, Smith AP, Mandic M, Athanassiou C, Watson-Hurst K, Jukic DM, Edington HD, Kirkwood JM, Becker D. Moschos SJ, et al. Oncogene. 2007 Jun 21;26(29):4216-25. doi: 10.1038/sj.onc.1210216. Epub 2007 Feb 12. Oncogene. 2007. PMID: 17297476

8

Endostatin plus interferon-alpha2b therapy for metastatic melanoma: a novel combination of antiangiogenic and immunomodulatory agents.

Moschos SJ, Odoux C, Land SR, Agarwala S, Friedland D, Volker KM, Sidor C, Wong M, Kirkwood JM. Moschos SJ, et al. Melanoma Res. 2007 Jun;17(3):193-200. doi: 10.1097/CMR.0b013e3281ad91a3. Melanoma Res. 2007. PMID: 17505265 Clinical Trial.

9

Present role and future potential of type I interferons in adjuvant therapy of high-risk operable melanoma.

Moschos S, Kirkwood JM. Moschos S, et al. Cytokine Growth Factor Rev. 2007 Oct-Dec;18(5-6):451-8. doi: 10.1016/j.cytogfr.2007.06.020. Epub 2007 Aug 10. Cytokine Growth Factor Rev. 2007. PMID: 17693125 Review.

10

Integrins and cancer.

Moschos SJ, Drogowski LM, Reppert SL, Kirkwood JM. Moschos SJ, et al. Oncology (Williston Park). 2007 Aug;21(9 Suppl 3):13-20. Oncology (Williston Park). 2007. PMID: 17927026 Free article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

93 results

Search Page